Cyproterone and its acetate Systematic (IUPAC) name 6-chloro-1β,2β-dihydro-17-hydroxy-3′H-cyclopropa[1,2]pregna-4,6-diene-3,20-dione Clinical data Trade names Androcur AHFS/Drugs.com Pregnancy cat. X Legal status ℞ Prescription only Routes oral, intramuscular Pharmacokinetic data Bioavailability 100% Metabolism hepatic Half-life about 40 hours Excretion 60% bile, 33% renal Identifiers CAS number 427-51-0 (acetate) ATC code G03 PubChem DrugBank ChemSpider UNII KEGG ChEBI ChEMBL Chemical data Formula C22H27ClO3 Mol. mass 416.9 SMILES & (what is this?)
Cyproterone acetate (also known as Androcur, Cyprostat, Cyproteron, Procur, Cyprone, Cyprohexal, Ciproterona, Cyproteronum, Neoproxil, Siterone) is an antiandrogen (i.e., it suppresses the actions of testosterone (and its metabolite dihydrotestosterone) on tissues). It acts by blocking androgen receptors which prevents androgens from binding to them and suppresses luteinizing hormone (which in turn reduces testosterone levels). Its main indications are prostate cancer, benign prostatic hyperplasia, priapism, hypersexuality and other conditions in which androgen action maintains the disease process. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transsexual people.
Until the development of leuprolide, cyproterone was one of the few drugs used to treat precocious puberty. It was also used in animal experimentation to investigate the actions of androgens in fetal sexual differentiation.
In addition, cyproterone acetate has weak progestational activity (i.e., it acts like progesterone) and can be used to treat hot flashes. As part of some combined oral contraceptive pills (Dianette in UK and Diane-35 in other countries) it decreases acne and hirsutism (male-pattern hair growth).
Cyproterone acetate is a synthetic derivative of 17-hydroxyprogesterone, and acts as an androgen receptor antagonist with weak progestational and glucocorticoid activity. Some portion is metabolized by hydrolysis to cyproterone and acetic acid. However, unlike many other steroid esters, cyproterone acetate is not extensively hydrolyzed, and much of its pharmacological activity is attributed to its acetate form. Cyproterone acetate has approximately three times the anti-androgenic activity of cyproterone.
Cyproterone acetate inhibits the steroidogenic enzyme 21-hydroxylase and to a lesser extent 3beta-hydroxysteroid dehydrogenase, both of which are needed to synthesize cortisol. The blockade of 21-hydroxylase can also result in reduced production of aldosterone, the primary mineralcorticoid hormone. Mutations in the gene encoding 21-hydroxylase are fairly common in the human population, therefore some patients may be affected more than others. Although cyproterone has some glucocorticoid activity, this is offset by the fact that cyproterone acetate inhibits cortisol production and can act as a competitive inhibitor of cortisol at the glucocorticoid receptor, thus its adrenosuppressive effects are usually fairly minor. However, since the glucocorticoid effects appear to be due to metabolites, rather than cyproterone acetate itself, the net effect may vary depending on the rate at which cyproterone acetate is metabolized. The progestational and glucocorticoid effects reduce production of gonadotropins, which usually results in lower testosterone levels, however the blockade of adrenal 21-hydroxylase results in the accumulation of androgen precursors which may be converted to testosterone, reducing the efficacy of the antiandrogen treatment. Due to the possibility of increased adrenal androgens, cyproterone acetate is sometimes combined with the 5-alpha-reductase inhibitor finasteride, and studies of hirsutism treatment show increased efficacy of this combination over cyproterone acetate alone. Some in vitro studies have suggested that cyproterone or cyproterone acetate may have a slight inhibitory effect on 5-alpha-reductase, however no significant reduction in DHT production has been observed in vivo.
Cyproterone acetate is metabolized by the CYP3A4 enzyme, forming the active metabolite 15β-hydroxycyproterone acetate, which retains its antiandrogen activity, but has reduced progestational activity. Therefore, use of cyproterone acetate in combination with substances which inhibit CYP3A4 may increase the progestational effects. Cyproterone acetate increases production of CYP3A4 by activating the pregnane x receptor.
The most serious potential side effect is liver toxicity, and patients should be monitored for changes in liver enzymes, especially if taking a high dose (200–300 mg/day). Toxicity is dose-dependent and the low doses used in birth control pills (2 mg) do not appear to represent a significant risk.
Suppression of adrenal function and reduced response to ACTH have been reported. Low cortisol levels may impair carbohydrate metabolism, and patients with diabetes mellitus may require adjustments in insulin dosage. Low aldosterone levels may lead to salt loss and hyperkalemia (excess potassium). Patients taking cyproterone should have their cortisol levels and electrolytes monitored, and if hyperkalemia develops, reduce the consumption of food having a high potassium content.
Used alone, cyproterone acetate does not appear to have a significant effect on blood clotting factors, but in combination with ethinylestradiol (as in combined oral contraceptive pills) presents an increased risk of deep vein thrombosis. There are conflicting reports as to whether there is a significant difference in the risk of thrombosis between oral contraceptives containing cyproterone acetate versus other types of combined oral contraceptives.
Cyproterone has been associated with depressive mood changes in some patients, presumably due to androgen deprivation. However, others have reported significant antidepressant effects. This may be due to its effect on adrenal hormones, as similar antidepressant effects have been observed with other adrenal suppressants, such as metyrapone.
Abrupt withdrawal of cyproterone acetate can be harmful, and the package insert from Schering AG recommends that the daily dose be reduced by no more than 50 mg, at intervals of several weeks. The primary concern is the manner in which cyproterone acetate affects the adrenal gland. Due to its glucocorticoid activity, high levels of cyproterone acetate may reduce ACTH, resulting in adrenal insufficiency if discontinued suddenly. In addition, although cyproterone acetate reduces androgen production in the gonads, it can increase adrenal androgen production, in some cases resulting in an overall rise in testosterone levels. Thus the sudden withdrawal of cyproterone acetate may result in undesirable androgenic effects. This is a particular concern because androgens, especially DHT, suppress adrenal function, further reducing cortisol production. In theory, 5-alpha-reductase inhibitors such as finasteride and dutasteride may be able to mitigate this effect somewhat by preventing the conversion of testosterone to the more potent DHT.
A paradoxical effect occurs with certain prostate cancer cells which have genetic mutations in their androgen receptors. These altered androgen receptors can be stimulated, rather than inhibited, by cyproterone. In such cases, withdrawal of cyproterone results in a reduction in cancer growth, rather than the opposite.
The pharmacokinetics of cyproterone are complicated due to its lipophilic nature. Although the mean elimination half-life is usually estimated at around 40 hours, this primarily reflects its accumulation in fat cells. Elimination from the bloodstream is considerably faster, and the amount stored in fat may be affected by food intake. Therefore it is recommended that this medication be given in divided doses 2-3 times per day, or in the form of a long-acting injection.
Dosage and administration
As an oral contraceptive, 2 mg cyproterone acetate is combined with 35 or 50 mcg ethinylestradiol and taken once daily for 21 days, followed by 7-day interval with placebo pills (Co-cyprindiol BAN sold as Dianette in UK, and Diane in US).
For the treatment of hypersexuality, severe hirsutism, or for the treatment of male-to-female transsexuals, 25 mg twice daily is usually sufficient, although up to 100 mg/day is permitted. As side effects are dose-dependent, treatment with the lowest effective dose is advisable.
Use during pregnancy is contraindicated, and for women of childbearing age, cyproterone should be administered with a combined oral contraceptive. To ensure that it does not interfere with regular withdrawal bleeding, additional cyproterone should be taken only on days 1-10 of a 28-day package of birth control pills.
Doses up to 300 mg/day are used for the treatment of metastatic prostate cancer, but at high doses the risk of serious hepatic toxicity or adrenal suppression requires careful monitoring. In treatment of prostate cancer, cyproterone is often co-administered with a GnRH agonist and a 5-alpha-reductase inhibitor.
- ^ Medicines and Healthcare products Regulatory Authority (2006-04-11). "Cyproterone Acetate" (PDF). http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2023735.pdf.
- ^ a b Berlex Canada, Inc. (2003-02-10). "Cyproterone Acetate Tablets and Injections Product Monographs (revised version)" (PDF). http://www.berlex.ca/html/docs/en/AndrocurEn.pdf.
- ^ Giorgi E, Shirley I, Grant J, Stewart J (1 March 1973). "Androgen dynamics in vitro in the human prostate gland. Effect of cyproterone and cyproterone acetate". Biochem J 132 (3): 465–74. PMC 1177610. PMID 4125095. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1177610.
- ^ Pham-Huu-Trung M, de Smitter N, Bogyo A, Girard F (1984). "Effects of cyproterone acetate on adrenal steroidogenesis in vitro". Horm Res 20 (2): 108–15. doi:10.1159/000179982. PMID 6237971.
- ^ Städtler F, Langner V (1985). "The effect of cyproterone and gonadotrophins on the adrenal gland of juvenile and adult rats. A morphological and morphometrical study". Pathol Res Pract 179 (4–5): 493–8. PMID 4001026.
- ^ Honer C, Nam K, Fink C, Marshall P, Ksander G, Chatelain R, Cornell W, Steele R, Schweitzer R, Schumacher C (2003). "Glucocorticoid receptor antagonism by cyproterone acetate and RU486". Mol Pharmacol 63 (5): 1012–20. doi:10.1124/mol.63.5.1012. PMID 12695529.
- ^ Holdaway I, Croxson M, Evans M, France J, Sheehan A, Wilson T, Ibbertson H (1983). "Effect of cyproterone acetate on glucocorticoid secretion in patients treated for hirsutism". Acta Endocrinol (Copenh) 104 (2): 222–6. PMID 6227191.
- ^ Bhargava AS, Kapp JF, Poggel HA, Heinick J, Nieuweboer B, Gunzel P (1981). "Effect of cyproterone acetate and its metabolites on the adrenal function in man, rhesus monkey and rat". Arzneimittelforschung 31 (6): 1005–9. PMID 6266428.
- ^ Welsh National Public Health Service, ATTRACT project.. "What therapies are available for women with PCOS with hirsutism other than Dianette?". http://www.attract.wales.nhs.uk/question_answers.cfm?question_id=2035.
- ^ Grunwald K, Rabe T, Schlereth G, Runnebaum B (1994). "[Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization]". Geburtshilfe Frauenheilkd 54 (11): 634–45. doi:10.1055/s-2007-1022355. PMID 8719011.
- ^ Frith R, Phillipou G (1985). "15-Hydroxycyproterone acetate and cyproterone acetate levels in plasma and urine". J Chromatogr 338 (1): 179–86. doi:10.1016/0378-4347(85)80082-7. PMID 3160716.
- ^ Fischl FH. (2001). "Pharmacology of Estrogens and Gestagens.". In Krause & Pachemegg (PDF). Menopause andropause.. Gablitz: Krause und Pachernegg. pp. 33–50. ISBN 3-901299-34-3. http://www.kup.at/kup/pdf/4975.pdf.
- ^ New Zealand Medicines and Medical Devices Safety Authority (2005-12-09). "Data Sheet: Diane 35 ED". http://www.medsafe.govt.nz/Profs/Datasheet/d/Diane35EDtab.htm.
- ^ Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998). "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions". J Clin Invest 102 (5): 1016–23. doi:10.1172/JCI3703. PMC 508967. PMID 9727070. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=508967.
- ^ Adverse Drug Reactions Advisory Committee (February 2004). "Australian Adverse Drug Reactions Bulletin, Volume 23, Number 1". http://www.tga.gov.au/adr/aadrb/aadr0402.htm.
- ^ Vasilakis-Scaramozza C, Jick H (2001). "Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives". Lancet 358 (9291): 1427–9. doi:10.1016/S0140-6736(01)06522-9. PMID 11705493.
- ^ Lidegaard Ø (2003). "Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol". J Obstet Gynaecol Can 25 (7): 575–7. PMID 12851669.
- ^ Itil TM (1983). "The discovery of antidepressant drugs by computer-analyzed human cerebral bio-electrical potentials (CEEG)". Prog Neurobiol 20 (3–4): 185–249. doi:10.1016/0301-0082(83)90003-5. PMID 6142498.
- ^ Healy DG, Harkin A, Cryan JF, Kelly JP, Leonard BE (1999). "Metyrapone displays antidepressant-like properties in preclinical paradigms". Psychopharmacology 145 (3): 303–8. doi:10.1007/s002130051062. PMID 10494579.
- ^ van der Vange N, Blankenstein M, Kloosterboer H, Haspels A, Thijssen J (1990). "Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone". Contraception 41 (4): 345–52. doi:10.1016/0010-7824(90)90034-S. PMID 2139843.
- ^ Stalvey J (2002). "Inhibition of 3beta-hydroxysteroid dehydrogenase-isomerase in mouse adrenal cells: a direct effect of testosterone". Steroids 67 (8): 721–31. doi:10.1016/S0039-128X(02)00023-5. PMID 12117620.
- ^ Prostate Cancer Research Institute.. "The Anti-Androgen Withdrawal Response". http://www.prostate-cancer.org/education/andeprv/aawr.html. Retrieved 2005-08-31.
- ^ BNF 54 September 2007
Androgens (G03B) Agonist SARMAC-262,356§ • Andarine (S-4)§ • BMS-564,929§ • LGD-2226§ • LGD-3303§ • Ostarine (MK-2866)§ • S-23§ • S-40503§ Antiandrogen Enzyme inhibitorsCYP17A1 inhibitors Estrogens and progestogens (G03C-D, L02) Progestogens/
Wikimedia Foundation. 2010.